Brain Metastasis: Diagnostic and Therapeutic Management
For patients with suspected brain metastasis, obtain contrast-enhanced MRI for diagnosis, and treat with stereotactic radiosurgery (SRS) for 1-4 lesions or surgical resection for single large symptomatic lesions, while avoiding routine whole-brain radiation therapy (WBRT) due to neurocognitive toxicity. 1, 2
Diagnostic Approach
Neuroimaging
- Contrast-enhanced MRI is the diagnostic standard for identifying brain metastases, superior to CT scanning for detecting small lesions and determining exact number and location 1
- Perform baseline MRI within 48 hours post-operatively to assess extent of resection 1
- Regular MRI surveillance is essential for monitoring treatment response 3
Tissue Diagnosis
- Obtain molecular genetic work-up of the brain metastasis itself rather than relying solely on primary tumor characteristics when feasible, as molecular profiles may differ and impact treatment selection for targeted therapy and immunotherapy 1
- Biopsy is particularly important when the primary tumor is unknown or when molecular changes may alter clinical decision-making 1
Treatment Algorithm by Clinical Scenario
Limited Brain Metastases (1-4 Lesions)
Single Brain Metastasis:
- Surgical resection is recommended for accessible single lesions, particularly those >3-4 cm causing mass effect or acute symptoms of raised intracranial pressure 1, 2
- Follow surgery with SRS to the resection cavity rather than WBRT to preserve neurocognitive function 1, 2
- For lesions <3-4 cm: SRS alone is the preferred approach (Level I evidence) 1, 2, 4
2-4 Brain Metastases:
- SRS alone is recommended as first-line treatment 1, 2
- Multiple resectable lesions may undergo surgical resection if causing significant mass effect, followed by SRS to cavities 1
Multiple Brain Metastases (5-10 Lesions)
- SRS may be considered if cumulative tumor volume is <15 mL 1
- Consider systemic therapy first for asymptomatic/oligosymptomatic patients with specific tumor types (see below) 1
- WBRT becomes an option when lesions are not amenable to SRS, though this should be weighed against neurocognitive decline 1, 2
Extensive Brain Metastases (>10 Lesions)
- WBRT should be considered for multiple symptomatic lesions not amenable to SRS, depending on neurological symptoms, size, location, and availability of CNS-active systemic therapy 1
- For patients with Karnofsky Performance Status ≤50 or <70 without systemic therapy options, supportive care without radiation therapy is appropriate as they do not derive survival benefit 2
Critical Caveat: Avoid Routine WBRT
Post-operative WBRT after neurosurgical resection or after SRS should be discouraged due to neurocognitive toxicity without survival benefit 1, 2. When WBRT is necessary:
- Offer memantine for neuroprotection 2
- Use hippocampal avoidance techniques in patients without hippocampal lesions and ≥4 months expected survival 2
Tumor-Specific Systemic Therapy Considerations
Non-Small Cell Lung Cancer (NSCLC)
With actionable mutations (EGFR, ALK, ROS1):
- Upfront systemic targeted therapy is recommended for asymptomatic/oligosymptomatic brain metastases 1
Without actionable mutations:
- PD-L1 ≥50%: Immune checkpoint inhibitor monotherapy 1
- PD-L1 <50%: Chemotherapy combined with immune checkpoint inhibition 1
Melanoma
- Combination ipilimumab and nivolumab is the preferred first-line treatment for asymptomatic patients, regardless of BRAF status 1
- For symptomatic BRAF-mutated brain metastases or patients requiring ≥4 mg dexamethasone: dabrafenib plus trametinib 1
HER2-Positive Breast Cancer
- Systemic treatment should be considered to delay WBRT in asymptomatic/oligosymptomatic patients with preserved performance status 1
HER2-Negative Breast Cancer
- After local treatment failure: consider capecitabine, eribulin, or carboplatin with bevacizumab 1
Small Cell Lung Cancer (SCLC)
- Platinum-based chemotherapy with or without immune checkpoint inhibition 1
- Prophylactic cranial irradiation (PCI) remains recommended for limited and extensive-stage SCLC with complete response to chemoradiotherapy 1
Special Surgical Considerations
Surgery is particularly indicated for:
- Patients requiring steroids who are candidates for immune checkpoint inhibition (to reduce steroid dependence) 1
- Acute symptoms of raised intracranial pressure 1
- Diagnostic uncertainty requiring tissue diagnosis 1
Key Clinical Pitfalls to Avoid
- Do not defer local therapy for symptomatic brain metastases regardless of systemic therapy plans 2
- Do not use WBRT reflexively - it significantly impairs neurocognitive function without improving survival in most scenarios 1, 2
- Do not assume primary tumor molecular profile matches brain metastasis - obtain updated molecular testing when possible 1
- Do not offer radiation therapy to patients with very poor performance status (KPS ≤50) without systemic options, as they derive no benefit 2